On Uncommon Illness Day, BIOTECanada and its members stand with Canadians and their households affected by a uncommon illness. In Canada, one in twelve folks have a uncommon dysfunction and roughly 3 million Canadians and their households face a debilitating illness that severely impacts their lives. Although every situation impacts solely a small variety of people, uncommon ailments collectively influence 300 million folks globally.
Whereas over 7,000 uncommon ailments have been recognized, there are only a few precise remedies out there, leaving most sufferers undiagnosed and with out entry to care. Addressing these unmet medical wants requires continued funding in analysis, innovation, and entry to care.
BIOTECanada is proud to help our members driving breakthroughs in uncommon illness remedies. Leveraging AI, genomics, and superior biotechnology, our members are deepening molecular understanding, advancing cell and gene therapies, and accelerating innovation by means of collaborations with international pharma and main Canadian analysis establishments.
The Canadian 2023 Nationwide Uncommon Illness Technique, backed by $1.4 billion in funding, is a crucial step ahead. Immediately, there are ongoing bilateral agreements with Ontario, New Brunswick, Saskatchewan, Alberta, Newfoundland and Labrador, and British Columbia that can assist advance affected person entry to uncommon illness remedies, early prognosis, and screening.
These federal and provincial collaborations are necessary milestones in lowering limitations to entry life-changing therapies, an effort BIOTECanada continues to champion. Extra must be executed.
As a part of this effort, BIOTECanada, as a member of the Implementation Advisory Group (IAG) for the Nationwide Technique for Medication for Uncommon Illnesses, stays dedicated to working with authorities, researchers, and business to advance biotechnology-driven options that enhance entry to modern remedies for these affected by uncommon ailments.
